COCH (Envoy Medical) Tariff Resilience Score: 5/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COCH Envoy Medical Inc COCH
24 GF Score
Price $0.74
GF Value $1.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Envoy Medical Tariff Resilience Score?

Envoy Medical COCH -6.06% 24 Tariff Resilience Score is 5 as of Jul. 15, 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 834 Medical Devices & Instruments companies, Envoy Medical ranks better than 79.26% on this metric.

Envoy Medical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Envoy Medical has Envoy Medical's reliance on imported medical components exposes it to tariff risks. However, the medical device industry often benefits from exemptions, and the company has some pricing power. Past tariffs have had a moderate impact, but strategic sourcing offers some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Envoy Medical might have Average Resilient.

Envoy Medical  (NAS:COCH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Envoy Medical Tariff Resilience Score Related Terms

COCH vs SRTS, QTI, MDAI: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Envoy Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Envoy Medical Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Envoy Medical's Tariff Resilience Score falls into.


COCH
24GF Score
Envoy Medical Inc COCH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Envoy Medical (COCH) has a Tariff Resilience Score of 5 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Envoy Medical ranks #173 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Envoy Medical's Tariff Resilience Score too high?
Envoy Medical's current Tariff Resilience Score is 5. Based on the distribution chart, Envoy Medical ranks #173 out of 834 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's Tariff Resilience Score compare to SRTS and QTI?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #173 out of 834 companies for Tariff Resilience Score. This places Envoy Medical in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Envoy Medical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.13, compared to a current price of $0.74 — trading 34.8% below its estimated fair value. The current Tariff Resilience Score is 5. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Envoy Medical (COCH), the current Tariff Resilience Score is 5 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued. The current stock price of $0.74 is trading 34.8% below its estimated GF Value™ of $1.13. GuruFocus considers Envoy Medical to be Possible Value Trap.

Key valuation signals for COCH:

  • Tariff Resilience Score: 5
  • GF Value™: $1.13 vs. price of $0.74 (34.8% below fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Envoy Medical Business Description

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score

Get the complete analysis for COCH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price
$1.13
GF Value